NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with Procarbazine, Lomustine, and Vincristine or Temozolomide

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5874-5880

  Wick, Wolfgang ^a   Hartmann, Christian ^a   Engel, Corinna ^a   Stoffels, Mandy ^a   Felsberg, Jörg ^a   Stockhammer, Florian ^a   Sabel, Michael C ^a   Koeppen, Susanne ^a   Ketter, Ralf ^a   Meyermann, Richard ^a   Rapp, Marion ^a   Meisner, Christof ^a   Kortmann, Rolf D ^a   Pietsch, Torsten ^a   Wiestler, Otmar D ^a   Ernemann, Ulrike ^a   Bamberg, Michael ^a   Reifenberger, Guido ^a   Von Deimling, Andreas ^a   Weller, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; IDH1 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; PCV PROTOCOL; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPLASTIC CARCINOMA; ANAPLASTIC OLIGOASTOCYTOMA; ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GLIOBLASTOMA; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; THROMBOEMBOLISM; TUMOR BLEEDING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRAIN TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GENETICS; GLIOMA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIERS ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; MUTATION; PROCARBAZINE; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS; VINCRISTINE; YOUNG ADULT;

EID: 73349134695     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6497     Document Type: Article

References (27)

1. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and metaanalysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
2. Weller M, Muller B, Koch R, et al: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276-3284, 2003
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
4. Batchelor T, Loeffler JS: Primary CNS lymphoma. J Clin Oncol 24:1281-1288, 2006
5. Levin VA, Silver P, Hannigan J, et al: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990
6. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
7. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006
8. Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006
9. Weller M, Berger H, Hartmann C, et al: Combined 1p/19q loss in oligodendroglial tumors: Predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937, 2007
10. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
11. Balss J, Meyer J, Mueller W, et al: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
12. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
13. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3:255-268, 1993
14. Kleihues P, Cavenee WK: Pathology and genetics of tumours of the nervous system, in World Health Organization Classification of Tumours (vol 1). Lyon, France, IARC Press, 2000
15. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
16. Jeuken J, Cornelissen S, Boots-Sprenger S, et al: Multiplex ligation-dependent probe amplification: A diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8:433-443, 2006
17. Felsberg J, Erkwoh A, Sabel MC, et al: Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14:121-130, 2004
18. Hartmann C, Mueller W, Lass U, et al: Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10-14, 2005
19. Möllemann M, Wolter M, Felsberg J, et al: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005
20. Krex D, Klink B, Hartmann C, et al: Long-term survival with glioblastoma multiforme. Brain 130:2596-2606, 2007
21. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Miller CR, Dunham CP, Scheithauer BW, et al: Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419-5426, 2006
23. Burger PC: What is an oligodendroglioma? Brain Pathol 12:257-259, 2002
24. Kros JM, Gorlia T, Kouwenhoven MC, et al: Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007
25. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
26. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
27. Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261-265, 2009